XTNT · XBRL financial data

Xtant Medical Holdings financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (XTNT's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	53,337	—	—	—	—	—
Revenue from contracts with customers	53,337	55,263	57,969	91,303	117,267	133,927
Cost of goods and services sold	18,945	22,773	25,832	35,836	49,051	49,654
Gross profit	34,392	32,490	32,137	55,467	68,216	84,273
Research and development	657	870	915	1,336	2,385	2,102
General and administrative	13,503	14,449	15,462	25,850	28,691	29,375
Total operating expenses	35,143	36,344	38,892	65,625	80,290	76,989
Operating income (loss)	(751)	(3,854)	(6,755)	(10,158)	(12,074)	7,284
Interest income	—	—	31	149	—	94
Interest expense	5,976	995	1,692	2,938	4,160	3,671
Other income (expense)	—	—	—	(49)	(33)	73
Income tax expense (benefit)	296	—	69	(1,697)	187	2,028
Net income (loss)	(7,023)	(4,849)	(8,485)	660	(16,449)	4,973
Earnings per share, basic USD per share	(0.25)	(0.06)	(0.09)	0.01	(0.12)	0.04
Earnings per share, diluted USD per share	(0.25)	(0.06)	(0.09)	0.01	(0.12)	0.03
Weighted average shares, basic thousands of shares	28,500	85,456	94,085	119,094	133,665	139,532
Weighted average shares, diluted thousands of shares	28,500	85,456	94,085	126,793	133,665	150,043

Fiscal years (XTNT's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	2,341	18,243	20,298	5,715	6,199	17,053
Accounts receivable	6,880	7,154	10,853	20,731	20,660	17,803
Inventory	21,408	17,945	17,285	36,885	38,634	30,263
Prepaid and other current assets	736	844	673	1,330	1,601	2,389
Total current assets	31,365	44,330	49,318	64,869	67,116	78,245
Property and equipment, net	4,347	5,212	5,785	8,692	10,131	6,202
Right-of-use asset	1,690	1,258	1,380	1,523	829	3,192
Goodwill	3,205	3,205	3,205	7,302	7,302	6,074
Total assets	41,466	54,692	60,229	92,612	93,837	94,145
Accounts payable	2,289	2,615	3,490	7,054	7,918	3,844
Accrued liabilities	6,120	4,349	5,496	10,419	7,771	10,626
Current portion of long-term debt	16,797	—	2,333	—	—	3,500
Total current liabilities	25,649	11,077	15,218	22,990	28,581	29,484
Long-term debt	—	11,787	9,687	17,167	22,038	11,026
Lease liability, non-current	1,303	842	972	759	166	2,665
Total liabilities	26,952	23,809	26,058	41,263	50,874	43,192
Accumulated deficit	(230,336)	(235,185)	(243,670)	(243,010)	(259,459)	(254,486)
Total stockholders' equity	14,514	30,883	34,171	51,349	42,963	50,953
Total liabilities and equity	41,466	54,692	60,229	92,612	93,837	94,145
Common shares outstanding (cover page) thousands of shares	77,818	87,314	108,897	130,217	139,068	140,068

Fiscal years (XTNT's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(7,023)	(4,849)	(8,485)	660	(16,449)	4,973
Stock-based compensation	1,084	2,209	2,464	2,739	4,117	2,892
Depreciation and amortization	2,079	1,332	1,292	3,174	4,224	5,223
Net cash from operating activities	(731)	439	(5,341)	(9,515)	(11,896)	12,546
Purchases of property and equipment	1,545	2,115	1,764	1,456	4,113	2,382
Net cash from investing activities	(1,304)	(1,890)	(1,559)	(24,784)	(3,730)	7,899
Proceeds from issuing common stock	620	18,426	9,311	14,011	—	—
Proceeds from long-term debt	—	—	—	4,761	5,000	—
Repayments of long-term debt	315	411	—	—	—	8,000
Net cash from financing activities	(861)	17,497	9,020	19,691	16,073	(9,570)
Net change in cash	(2,896)	16,046	2,120	(14,584)	298	11,107

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Xtant Medical Holdings	9,870	23,031	(7,308)*	140.3M	1.4 quarters	Q2 FY26 10-QJun 30, 2026
Hyperfine	43,458	3,904	(7,268)*	not reported	6.0 quarters	Q2 FY26 10-QJun 30, 2026
Vivani Medical	19,894	not reported	(6,035)*	90.2M	3.3 quarters	Q2 FY26 10-QJun 30, 2026
Vivos	2,336	36	(740)*	494.2M	3.2 quarters	Q2 FY26 10-QJun 30, 2026
Alpha Pro Tech	18,901	not reported	2,213*	10.2M	—	Q2 FY26 10-QJun 30, 2026
Nuo Therapeutics	449	not reported	(236)*	48.4M	1.9 quarters	Q2 FY26 10-QJun 30, 2026
Fractyl Health	47,140	not reported	(15,901)*	159.2M	3.0 quarters	Q2 FY26 10-QJun 30, 2026
Milestone Scientific	2,067	not reported	(585)*	88.7M	3.5 quarters	Q2 FY26 10-QJun 30, 2026
Vicarious Surgical	1,407	not reported	(6,325)	not reported	0.6 quarters	Q1 FY26 10-QMar 31, 2026

Not investment advice. Not affiliated with the U.S. SEC.